Accendra Health Advances Debt Reduction Strategy Amid Turnaround Efforts
Accendra Health, Inc. (NYSE: ACH), formerly known as Owens & Minor, is making significant strides in its multiyear turnaround strategy by focusing on at-home medicine and divesting its hospital supply unit. The company recently completed a refinancing deal that extends debt maturities and reduces gross debt by approximately $100 million, thereby improving its liquidity position and enhancing the likelihood of successful long-term deleveraging. Despite these positive structural changes, the stock has underperformed, losing about 40% of its value over the past year due to excessive leverage, weak margins, and questionable M&A history. Management has reaffirmed its full-year guidance, although analysts expect EBITDA to land at the lower end of the outlook due to ongoing margin pressure and slow volume growth. An analyst maintains a Buy rating with a price target of around $7 by 2030, citing increased confidence from the improved capital structure. However, the investment is still considered speculative given the company's high leverage levels. This analysis highlights the balance between financial restructuring progress and operational challenges facing Accendra Health as it attempts to stabilize its business model.
Wire timeline
Accendra Health Advances Debt Reduction Strategy Amid Turnaround Efforts
Accendra Health, Inc. (NYSE: ACH), formerly known as Owens & Minor, is making significant strides in its multiyear turnaround strategy by focusing on at-home medicine and divesting its hospital supply unit. The company recently completed a refinancing deal that extends debt maturities and reduces gross debt by approximately $100 million, thereby improving its liquidity position and enhancing the likelihood of successful long-term deleveraging. Despite these positive structural changes, the stock has underperformed, losing about 40% of its value over the past year due to excessive leverage, weak margins, and questionable M&A history. Management has reaffirmed its full-year guidance, although analysts expect EBITDA to land at the lower end of the outlook due to ongoing margin pressure and slow volume growth. An analyst maintains a Buy rating with a price target of around $7 by 2030, citing increased confidence from the improved capital structure. However, the investment is still considered speculative given the company's high leverage levels. This analysis highlights the balance between financial restructuring progress and operational challenges facing Accendra Health as it attempts to stabilize its business model.
All Articles on Seeking Alpha